BioNTech, a leading biopharmaceutical company, has announced plans to fully acquire InstaDeep, an artificial intelligence company specializing in drug discovery, design, and development. This acquisition will allow BioNTech to cement its position as a leader in AI-powered drug development. The two companies hope to drive innovation and improve patient care by combining BioNTech’s expertise in biopharmaceutical research with InstaDeep’s AI capabilities. This acquisition is expected to enhance BioNTech’s ability to design next-generation immunotherapies while speeding up the drug development process.
The acquisition of InstaDeep by BioNTech will help the company expand its capabilities in using AI for drug discovery and the development of advanced immunotherapies and vaccines to combat diseases with significant unmet medical needs. Furthermore, it intends to incorporate AI and machine learning technologies into all of its operations.
The CEO of InstaDeep, Karim Beguir, spoke about the rapid growth of AI and stated that the company’s goal has always been to ensure that it benefits everyone. InstaDeep has created AI systems that address complex issues in fields such as biology, energy, logistics, and electronic design. InstaDeep received $100 million from equity investors, including BioNTech, in January 2022.
With this acquisition, BioNTech’s workforce will gain 240 experts in AI, machine learning, bioengineering, data science, and software development. Also, BioNTech will expand its network of research collaborators and expand its presence in the United States, Europe, Africa, and the Middle East.
The total cost of the acquisition includes a cash payment of about £362 million for shares that BioNTech does not yet own, as well as potential additional payments of up to £200 million based on future performance milestones.
BioNTech may overtake InstaDeep, a UK-based AI firm, completely by the end of June, with InstaDeep becoming a subsidiary of BioNTech. InstaDeep will play an important role in BioNTech’s growing portfolio of AI and machine learning projects while continuing to serve clients globally in various industries.
According to BioNTech CEO Ugur Sahin, the acquisition of InstaDeep allows the company to integrate modern AI technologies into its research, drug discovery, manufacturing, and deployment processes. The goal of this acquisition is to make BioNTech a technology company where AI is an integral part of their work.
The company longs to establish itself as a leader in biopharmaceutical research and AI, working together to develop cutting-edge immunotherapies that will significantly improve patient care and, ultimately, aid in the fight against cancer and other illnesses.
The acquisition of InstaDeep by BioNTech is a strategic move that will significantly strengthen the company’s position as a pioneer in AI-powered drug discovery, design, and development. The combination of BioNTech’s biopharmaceutical research expertise and InstaDeep’s AI expertise will develop novel immunotherapies that will significantly improve patient care. With this acquisition, BioNTech will be well-positioned to continue its mission of using AI and biotechnology to improve the lives of cancer and other disease patients.
Article Source: Reference Article
Freely available courses to learn each and every aspect of bioinformatics.
Stay updated with the latest discoveries in the field of bioinformatics.
Dr. Tamanna Anwar is a Scientist and Co-founder of the Centre of Bioinformatics Research and Technology (CBIRT). She is a passionate bioinformatics scientist and a visionary entrepreneur. Dr. Tamanna has worked as a Young Scientist at Jawaharlal Nehru University, New Delhi. She has also worked as a Postdoctoral Fellow at the University of Saskatchewan, Canada. She has several scientific research publications in high-impact research journals. Her latest endeavor is the development of a platform that acts as a one-stop solution for all bioinformatics related information as well as developing a bioinformatics news portal to report cutting-edge bioinformatics breakthroughs.